Radiprodil

Radiprodil

Clinical data
Other names	RGH-896; RGH896
Routes of administration	Oral [1]
Drug class	NR2B subunit-containing NMDA receptor negative allosteric modulator
Identifiers
IUPAC name 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide
CAS Number	496054-87-6
PubChem CID	10200813
DrugBank	DB12260
ChemSpider	8376312
UNII	5XGC17ZKUF
ChEMBL	ChEMBL182066
CompTox Dashboard (EPA)	DTXSID80964297
Chemical and physical data
Formula	C21H20FN3O4
Molar mass	397.406 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCC1CC2=CC=C(C=C2)F)C(=O)C(=O)NC3=CC4=C(C=C3)NC(=O)O4
InChI InChI=1S/C21H20FN3O4/c22-15-3-1-13(2-4-15)11-14-7-9-25(10-8-14)20(27)19(26)23-16-5-6-17-18(12-16)29-21(28)24-17/h1-6,12,14H,7-11H2,(H,23,26)(H,24,28) Key:GKGRZLGAQZPEHO-UHFFFAOYSA-N

Radiprodil (INN Tooltip International Nonproprietary Name; developmental code name RGH-896) is an NR2B (GluN2B; GRIN2B) subunit-selective NMDA receptor negative allosteric modulator which is under development for the treatment of neurodevelopmental disorders, focal cortical dysplasia, tuberous sclerosis, behavioral disorders, and seizures. ^{[1] [2] [3]} It is taken orally. ^[1] The drug is being developed by GRIN Therapeutics. ^[1] As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures. ^[1] THe drug was first described in the scientific literature by 2003. ^[4]

References

1. "GRIN Therapeutics". AdisInsight. 28 December 2025. Retrieved 16 January 2026.
2. Auvin S, Dozières-Puyravel B, Avbersek A, Sciberras D, Collier J, Leclercq K, Mares P, Kaminski RM, Muglia P (March 2020). "Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome". Ann Clin Transl Neurol. 7 (3): 343–352. doi:10.1002/acn3.50998. PMC   7085998 . PMID   32106360.
3. Mullier B, Wolff C, Sands ZA, Ghisdal P, Muglia P, Kaminski RM, André VM (September 2017). "GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors". Neuropharmacology. 123: 322–331. doi:10.1016/j.neuropharm.2017.05.017. PMID   28533163.
4. Farkas, S., Horvath, C., & Nagy, J. (2003). RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. Program No. 382.8. 2003 Abstract Viewer/Itinerary Planner. Washington, DC. Society for Neuroscience. https://scholar.google.com/scholar?cluster=1937207076977424379